UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03933 UNITED LAB

Not Yet Opened 01-14 16:08:06

11.730

-0.500

-4.09%

High12.280	Low11.700	Vol14.67M
Open12.280	D1 Closing12.230	Amplitude4.74%
Mkt Cap23.14B	Tradable Cap23.14B	Total Shares1.97B
T/O174.54M	T/O Rate0.74%	Tradable Shares1.97B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"UNITED LAB","latestPrice":11.73,"timestamp":1768378086007,"preClose":12.23,"halted":0,"volume":14670300,"delay":0,"floatShares":1973000000,"shares":1973000000,"eps":1.463938,"marketStatus":"Not Yet Opened","change":-0.5,"latestTime":"01-14 16:08:06","open":12.28,"high":12.28,"low":11.7,"amount":174541699,"amplitude":0.047424,"askPrice":11.74,"askSize":2000,"bidPrice":11.73,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":1.702,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":0,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":12.23,"dividendRate":0.041947,"openAndCloseTimeList":[[1768354200000,1768363200000],[1768366800000,1768377600000]],"volumeRatio":1.1033226133096272,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","LU1003077747.HKD","LU1989771016.USD","03165","ALT","AZN.UK","IE00BJLML261.HKD","LU0823434583.USD","MTSR","IE00BN8TJ469.HKD","LU0306806265.USD","LU1035775433.USD","00656","OPK","SG9999002224.SGD","IE00BJJMRX11.SGD","SG9999015986.USD","600196","BK4566","IE00B4JS1V06.HKD","LU0499090636.EUR","VKTX","SGXZ99366536.SGD","IE0002141913.USD","LLY","03692","LU1720051017.SGD","LU0345777147.USD","SG9999014906.USD","IE0005OL40V9.USD","BK0188","SG9999013999.USD","LU1061106388.HKD","SRRK","LU0256863902.USD","LU0106261372.USD","LU0964806797.USD","BK0028","03933","IE00BK4W5M84.HKD","AMGN","LU2106854487.HKD","GPCR","LU0130517989.USD","LU1323610961.USD","MRK","LU0211328371.USD","LU1989772840.SGD","02105"],"gpt_icon":1},{"id":"2590312981","title":"BRIEF-United Laboratories International Says Unit's Levofloxacin Eye Drops Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312981","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590312981?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:09","pubTimestamp":1765274969,"startTime":"0","endTime":"0","summary":"BRIEF-United Laboratories International Says Unit's Levofloxacin Eye Drops Approved By NMPADec 9 (Reuters) - United Laboratories International Holdings Ltd 3933.HK:LEVOFLOXACIN EYE DROPS SUBMITTED BY UNIT APPROVED BY NMPAFurther company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"1102141054","title":"UNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1102141054","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102141054?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:58","pubTimestamp":1765274302,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2590266314","title":"United Laboratories International -  Levofloxacin Eye Drops Submitted by Unit Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590266314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590266314?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:53","pubTimestamp":1765274020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2590331442","title":"TUL Wins China Approval for Levofloxacin Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2590331442","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590331442?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:53","pubTimestamp":1765273988,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Ltd.  announced that its subsidiary, Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, has received regulatory approval from the China National Medical Products Administration for its Levofloxacin Eye Drops , with drug approval number H20256135. This approval expands TUL's ophthalmic drug portfolio and solidifies its position in the field of ophthalmic anti-infective treatment. The product is also included in the Category A of the National Medical Insurance Drug List . There is no indication that grant funding or regulatory approval was obtained by organizations other than TUL.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. pub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9MNMtJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2589805306","title":"The Bull Case For United Laboratories International Holdings (SEHK:3933) Could Change Following Key Cefoperazone-Sulbactam Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589805306","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589805306?lang=en_us&edition=fundamental","pubTime":"2025-12-07 22:17","pubTimestamp":1765117078,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List.\nThis outcome strengthens the company’s anti-infective portfolio by validating a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/the-bull-case-for-united-laboratories-international-holdings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/the-bull-case-for-united-laboratories-international-holdings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UBCP","BK1191","03933","BK4211"],"gpt_icon":0},{"id":"2589482630","title":"United Laboratories (SEHK:3933): Evaluating a Low P/E Valuation After New China Drug Consistency Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589482630","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589482630?lang=en_us&edition=fundamental","pubTime":"2025-12-06 17:20","pubTimestamp":1765012828,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings (SEHK:3933) just cleared a meaningful regulatory hurdle, with its subsidiary’s Cefoperazone and Sulbactam injection passing China’s consistency evaluation, reinforcing its anti infective franchise and long term growth platform.\nSee our latest analysis for United Laboratories International Holdings.\nDespite the setback of a roughly 27 percent 3 month share price return, the stock has still delivered a strong 1 year total shareholder return near 20...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-sehk3933-evaluating-a-low-pe-valuation-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-sehk3933-evaluating-a-low-pe-valuation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1191","UBCP","03933","BK4211"],"gpt_icon":0},{"id":"1156292861","title":"The United Laboratories (03933) Announces Monthly Share Capital Return: Authorized Capital and Issued Shares Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=1156292861","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156292861?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:24","pubTimestamp":1764753887,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Limited (stock code: 03933) has released its Monthly Return for Equity Issuer for the period ended 30 November 2025. According to the announcement, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"gpt_icon":0},{"id":"2587586731","title":"Why United Laboratories (SEHK:3933) Is Up 8.8% After Landmark Drug Approval in China and What’s Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2587586731","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587586731?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:24","pubTimestamp":1764339859,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings recently announced that its Cefoperazone Sodium and Sulbactam Sodium for Injection has passed the consistency evaluation by the China National Medical Products Administration.\nThis achievement marks a significant regulatory milestone and highlights the company's ongoing focus on expanding its anti-infective product portfolio through research and development.\nWe'll explore how this successful product evaluation strengthens United Laboratories'...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/why-united-laboratories-sehk3933-is-up-88-after-landmark-dru","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/why-united-laboratories-sehk3933-is-up-88-after-landmark-dru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UBCP","BK1191","BK4211","03933","LARK"],"gpt_icon":0},{"id":"2586255603","title":"Update: The United Laboratories Unit's Antibiotic Passes Chinese Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586255603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586255603?lang=en_us&edition=fundamental","pubTime":"2025-11-26 18:42","pubTimestamp":1764153765,"startTime":"0","endTime":"0","summary":"The United Laboratories International  said Cefoperazone Sodium and Sulbactam Sodium for Injection passed China National Medical Products Administration's consistency evaluation, a Wednesday Hong Kong bourse filing said.The drug was submitted by the Zhongshan Branch of Zhuhai United Laboratories, a unit of the firm.The drug is a cephalosporin antibiotic which, when used as monotherapy, is indicated for the treatment of various infections, including respiratory tract infections, urinary tract infections, meningitis, and genital tract infections.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","03933","UBCP","BK4211"],"gpt_icon":0},{"id":"2586539272","title":"BRIEF-United Laboratories International Says Cefoperazone Sodium And Sulbactam Sodium For Injection Passed Consistency Evaluation By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2586539272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586539272?lang=en_us&edition=fundamental","pubTime":"2025-11-26 18:19","pubTimestamp":1764152369,"startTime":"0","endTime":"0","summary":"BRIEF-United Laboratories International Says Cefoperazone Sodium And Sulbactam Sodium For Injection Passed Consistency Evaluation By NMPANov 26 (Reuters) - United Laboratories International Holdings L","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X10ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"1196299660","title":"UNITED LAB (03933): Cefoperazone Sodium and Sulbactam Sodium for Injection Passes Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1196299660","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196299660?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:12","pubTimestamp":1764148349,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2586232012","title":"United Laboratories International - Cefoperazone Sodium and Sulbactam Sodium for Injection Passed Consistency Evaluation by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2586232012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586232012?lang=en_us&edition=fundamental","pubTime":"2025-11-26 16:59","pubTimestamp":1764147588,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X10ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2586170232","title":"TUL Wins Regulatory Approval for Cefoperazone-Sulbactam Injection in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2586170232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586170232?lang=en_us&edition=fundamental","pubTime":"2025-11-26 16:59","pubTimestamp":1764147555,"startTime":"0","endTime":"0","summary":"The United Laboratories International Holdings Ltd.  announced that its product, Cefoperazone Sodium and Sulbactam Sodium for Injection , has passed the consistency evaluation of quality and efficacy for generic drugs by the China National Medical Products Administration. This regulatory approval, achieved by TUL's wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, reinforces the company's position in the anti-infective field. The product is indicated for a variety of bacterial infections and is included in the Category B of the National Medical Insurance Drug List . No other organizations were noted as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United La","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2zcyZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2586724475","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:39","pubTimestamp":1764077944,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upRewrites paragraph 1, adds Lilly valuation milestone in paragraph 3, updates with Novo trial details in paragraphs 9-0. Promising results of Novo Nordisk's NOVOb.CO experimental obesity drug, amycretin, from a mid-stage trial could give the drugmaker much-needed heft to reclaim lost ground in the weight-loss market, which is projected to reach $150 billion by next decade.Novo said the drug appeared safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects. Late-stage trials are planned for 2026. Amycretin has a dual-mode action, targeting GLP-1 and amylin hormones.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1057294990.SGD","LU1069347547.HKD","03692","LU2168564149.EUR","VKTX","LU0265550359.USD","MRK","03933","MTSR","SG9999014542.SGD","LU1061106388.HKD","GPCR","ALT","LU0109391861.USD","LU0557290698.USD","LU2168563687.JPY","SG9999011175.SGD","LU2746668461.USD","LU0738911758.USD","LU0225771236.USD","LU2063271972.USD","LU2265009873.SGD","LU0553294199.USD","IE00B4R5TH58.HKD","LU0079474960.USD","03165","SG9999015945.SGD","SRRK","BK4592","LU0949170772.SGD","LU0094547139.USD","LU0198837287.USD","LU1023059063.AUD","LU0820561909.HKD","LU0964806797.USD","IE00BLSP4239.USD","SG9999015986.USD","LU0353189680.USD","AZN.UK","LU1066051225.USD","SG9999013999.USD","LU2168564065.EUR","LU0823416689.USD","LU1551013342.USD","OPK","IE0004445239.USD","02105"],"gpt_icon":1},{"id":"1179046124","title":"HK Stock Movement | UNITED LAB (03933) Rises Over 4% Before Noon as New Diabetes Drug Gains Attention; Semaglutide Injection Expected to Launch Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1179046124","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179046124?lang=en_us&edition=fundamental","pubTime":"2025-11-25 11:48","pubTimestamp":1764042502,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million. The company recently highlighted its diabetes...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2584180499","title":"Could United Laboratories (SEHK:3933) Leverage TUL01101’s Trial Success to Strengthen Its Innovation Edge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180499","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584180499?lang=en_us&edition=fundamental","pubTime":"2025-11-20 13:21","pubTimestamp":1763616073,"startTime":"0","endTime":"0","summary":"United Laboratories International Holdings recently reported the completion of a Phase II clinical trial in China for TUL01101 Tablets, targeting adult patients with moderate-to-severe atopic dermatitis, and noted significant efficacy and favorable safety results across all tested doses.\nThe rapid reduction in eczema severity as early as the first week highlights the investigational drug's potential to address an unmet clinical need in dermatology.\nLet's explore how the robust efficacy...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/could-united-laboratories-sehk3933-leverage-tul01101s-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/could-united-laboratories-sehk3933-leverage-tul01101s-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UBCP","03933","BK1191","BK4211"],"gpt_icon":0},{"id":"1170157547","title":"United Laboratories (3933) Announces Vesting of 3,369,800 Award Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1170157547","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170157547?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:21","pubTimestamp":1763043680,"startTime":"0","endTime":"0","summary":"United Laboratories (3933) disclosed that, under the 2023 Share Award Scheme, a total of 3,369,800 Award Shares vested in designated recipients on 13 November 2025. These shares were granted in line...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"gpt_icon":0},{"id":"1163860140","title":"UNITED LAB (03933): Approximately 3.3698 Million Reward Shares Vested","url":"https://stock-news.laohu8.com/highlight/detail?id=1163860140","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163860140?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:16","pubTimestamp":1763043369,"startTime":"0","endTime":"0","summary":"UNITED LAB (03933) announced that a total of 3.3698 million reward shares have been vested to the relevant recipients on November 13, 2025, in accordance with the terms of the 2023 Share Reward Scheme and the achievement of the 2024 performance targets.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2582338187","title":"United Laboratories Unit Reports Positive Phase 2 Results for Atopic Dermatitis Drug; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582338187","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582338187?lang=en_us&edition=fundamental","pubTime":"2025-11-11 10:17","pubTimestamp":1762827460,"startTime":"0","endTime":"0","summary":"United Laboratories International  said its wholly owned unit, Zhuhai United Laboratories, has completed a Phase 2 clinical trial in China for TUL01101 tablets, a Class 1 new drug for treating moderate-to-severe atopic dermatitis, according to a Monday bourse filing.Shares of the firm were up nearly 3% in Tuesday morning trade.The multicenter trial enrolled 201 adult patients and tested three dose groups over 12 weeks.All doses showed significant efficacy, with Eczema Area and Severity Index  score reductions of up to 87.9% and an EASI-75 response rate as high as 84%, according to the filing.The drug also demonstrated a favorable safety profile, with most adverse events being mild to moderate.Following the positive results, the company has begun discussions with regulators and is initiating a Phase 3 clinical trial in China.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4211","03933","EASI","BK1191","UBCP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0417},{"period":"3month","weight":-0.1438},{"period":"6month","weight":-0.1862},{"period":"1year","weight":0.1031},{"period":"ytd","weight":0.0121}],"compareEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0535},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.0876},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.0534}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.03386},{"month":2,"riseRate":0.722222,"avgChangeRate":0.07509},{"month":3,"riseRate":0.666667,"avgChangeRate":0.040428},{"month":4,"riseRate":0.611111,"avgChangeRate":0.081119},{"month":5,"riseRate":0.666667,"avgChangeRate":0.040685},{"month":6,"riseRate":0.277778,"avgChangeRate":-0.012388},{"month":7,"riseRate":0.526316,"avgChangeRate":0.011895},{"month":8,"riseRate":0.473684,"avgChangeRate":0.025474},{"month":9,"riseRate":0.421053,"avgChangeRate":-0.006971},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000903},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023163},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011153}],"exchange":"SEHK","name":"UNITED LAB","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest UNITED LAB(03933) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"UNITED LAB,03933,UNITED LAB股票,UNITED LAB股票老虎,UNITED LAB股票老虎国际,UNITED LAB行情,UNITED LAB股票行情,UNITED LAB股价,UNITED LAB股市,UNITED LAB股票价格,UNITED LAB股票交易,UNITED LAB股票购买,UNITED LAB股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UNITED LAB(03933),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest UNITED LAB(03933) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}